Brief: Verastem Oncology Exercises Option Early to License VS-7375

Verastem

14/01/2025 12:33

Jan 14 (Reuters) - Verastem Inc  VSTM.O :
    * VERASTEM ONCOLOGY EXERCISES OPTION EARLY TO LICENSE
VERSUS-7375,
AN ORAL KRAS G12D (ON/OFF) INHIBITOR, FROM GENFLEET THERAPEUTICS
AND PROVIDES PRELIMINARY CLINICAL UPDATE ON PHASE 1 STUDY IN
CHINA
    * VERASTEM INC - TO FILE U.S. IND APPLICATION FOR
VERSUS-7375 IN
Q1 2025

Source text:  ID:nBw6N5yFqa 
Further company coverage:  VSTM.O 

 ((Reuters.Briefs@thomsonreuters.com;))